Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sputum

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    624 result(s) found for: Sputum. Displaying page 3 of 32.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2018-004267-32 Sponsor Protocol Number: CQAW039E12201 Start Date*: 2019-04-10
    Sponsor Name:Novartis Pharma AG
    Full Title: A multi-center, proof-of-mechanism study of multiple, oral doses of fevipiprant (QAW039) in COPD patients with eosinophilia
    Medical condition: Chronic obstructive pulmonary disease with eosinophilia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-009869-34 Sponsor Protocol Number: BAYq3939/12965 Start Date*: 2009-06-08
    Sponsor Name:Bayer HealthCare AG
    Full Title: Randomized, placebo-controlled, double-blind, multi center study to evaluate the safety and efficacy of ciprofloxacin inhale compared to placebo in patients with non-cystic fibrosis bronchiectasis
    Medical condition: Idiopathic and post-pneumonic non-Cystic Fibrosis Bronchiectasis in pulmonary stable patients (defined as FEV1 of > 35 % and < 80 percent of predicted)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006445 Bronchiectasis LLT
    9.1 10006445 Bronchiectasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001762-14 Sponsor Protocol Number: 69765 Start Date*: 2020-07-29
    Sponsor Name:University Medical Center Groningen
    Full Title: Evaluation of the anti-inflammatory effects of glycopyrronium added to indacaterol/mometasone on the allergen-induced late asthmatic response
    Medical condition: Asthma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002125-35 Sponsor Protocol Number: SMR-2591 Start Date*: 2014-12-18
    Sponsor Name:Algipharma AS
    Full Title: A randomized double-blind, placebo-controlled cross-over study of inhaled alginate oligosaccharide (OligoG) for 28 days in subjects with Cystic Fibrosis using aztreonam due to chronic colonization ...
    Medical condition: Cystic Fibrosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003581-25 Sponsor Protocol Number: APA-III Start Date*: 2015-05-26
    Sponsor Name:University Hospital Tuebingen
    Full Title: Anti-inflammatory pulmonal therapy of CF-patients with Amitriptyline and Placebo - Randomised, double-blind, placebo-controlled cohort trial
    Medical condition: Amitriptyline reduces ceramide concentrations in bronchial epithelial cells and reduces cell death and reduces the deposition of DNA on the respiratory epithelium. This reduction promotes the elimi...
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001137-41 Sponsor Protocol Number: 666 Start Date*: 2018-06-26
    Sponsor Name:Hvidovre Hospital. Dep of Respiratory Medicine
    Full Title: Use of Omalizumab will increase the pregnancy rate, proof of concept study, where women with asthma and infertility will be treated three times with weight and IgE balanced dosis at the sixth day o...
    Medical condition: infertility within female asthma patients as a result of systemic inflamation.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001309-95 Sponsor Protocol Number: MPH966-2-01 Start Date*: 2018-11-30
    Sponsor Name:Mereo BioPharma 4 Ltd
    Full Title: A Phase 2, proof-of-concept, multicentre, double-blind, randomised, dose-ascending, sequential group, placebo-controlled study to evaluate the mechanistic effect, safety, and tolerability of 12 wee...
    Medical condition: Alpha-1 antitrypsin deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10001806 Alpha-1 anti-trypsin deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) DK (Completed) ES (Ongoing) PL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022271-59 Sponsor Protocol Number: 242-09-213 Start Date*: 2011-07-19
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of Delamanid (OPC-67683) Administered Orally as 200 mg Total Daily Dos...
    Medical condition: Pulmonary Multidrug-resistant Tuberculosis (MDR TB)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10037443 Pulmonary tuberculosis, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) EE (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2009-014523-23 Sponsor Protocol Number: ATB1 Start Date*: 2010-01-28
    Sponsor Name:Stichting longgeneeskunde Fryslan
    Full Title: The effect of treatment with high dose vitamin D on airway inflammation in non-atopic asthma
    Medical condition: Non-atopic asthma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020440-35 Sponsor Protocol Number: D589BC00004 Start Date*: 2011-09-16
    Sponsor Name:Imperial College London
    Full Title: GR activity in induced sputum macrophages, and a change in inflammatory biomarkers 2-hours after a single dose of either Symbicort®/Budesonide/Formoterol or placebo in Chronic Obstructive Pulmonary...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-003344-62 Sponsor Protocol Number: mitHDAC Start Date*: 2005-11-15
    Sponsor Name:Imperial College
    Full Title: Effect of theophylline on histone deacetylase activity: enhancement of in-vitro glucocorticoid function in patients with COPD.
    Medical condition: Chronic Obstructive Lung Disease (COPD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-000531-88 Sponsor Protocol Number: SP1-2011 Start Date*: 2011-06-27
    Sponsor Name:FONDAZIONE IRCCS CA` GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO
    Full Title: Ceftidoren versus levofloxacin in the treatment of patients with Acute Exacerbations of Chronic Bronchitis (AECB). Multi-centre, open-label, randomised, levofloxacin-controlled, parallel groups s...
    Medical condition: EXACERBATION OF CHRONIC BRONCHITIS
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002173-22 Sponsor Protocol Number: 201800406 Start Date*: 2018-12-04
    Sponsor Name:University Medical Center Groningen
    Full Title: Anti-inflammatory effects of tiotropium in patients with stable COPD
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000338-10 Sponsor Protocol Number: 0606 Start Date*: 2006-02-24
    Sponsor Name:NHS Lothian Health Board [...]
    1. NHS Lothian Health Board
    2. Edinburgh Research and Innovation
    Full Title: Can long term nebulised gentamicin reduce the bacterial burden, break the vicious cycle of inflammation and improve quality of life in patients with bronchiectasis?
    Medical condition: Bronchiectasis is respiratory disease with damaged airways. Such patients have frequent bacterial chest infections. The aim of our study is to assess whether nebulised gentamicin 80mg twice daily w...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-002707-40 Sponsor Protocol Number: AGO/2007/004 Start Date*: 2007-06-28
    Sponsor Name:University Hospital Ghent
    Full Title: The effect of inhalation with hypertonic saline (7%) on lung function and sputum rheology in Cystic Fibrosis patients
    Medical condition: Mucoviscidose
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011763 Cystic fibrosis lung LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011452-21 Sponsor Protocol Number: Start Date*: 2009-09-18
    Sponsor Name:University Hospitals of Leicester NHS trust
    Full Title: Study of the effectiveness of Voriconazole in the treatment of Aspergillus fumigatus associated asthma
    Medical condition: Asthma with sensitization to aspergillus and isolation in sputum.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-000311-98 Sponsor Protocol Number: P2005V3 Start Date*: 2005-11-09
    Sponsor Name:University of Nottingham
    Full Title: A randomised controlled trial (pilot study) of the use of macerated garlic oil in patients with cystic fibrosis who have pulmonary infection with Pseudomonas aeruginosa
    Medical condition: Chronic pulmonary infection with Pseudomonas aeruginosa in patients with cystic fibrosis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-006980-22 Sponsor Protocol Number: TR02-105 Start Date*: 2007-06-14
    Sponsor Name:Transave, Inc.
    Full Title: MULTIDOSE SAFETY AND TOLERABILITY STUDY OF DOSE ESCALATION OF LIPOSOMAL AMIKACIN FOR INHALATION (ARIKACE™) IN CYSTIC FIBROSIS PATIENTS WITH CHRONIC INFECTIONS DUE TO PSEUDOMONAS AERUGINOSA
    Medical condition: Cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011762 Cystic fibrosis LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-001005-25 Sponsor Protocol Number: CCD-1201-PR-0079 Start Date*: 2012-08-02
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: A randomised, double-blind, double-dummy, placebo and active-controlled, three-way crossover study to evaluate the safety, tolerability and efficacy of 28-day inhaled CHF 6001 DPI (1200microgrammes...
    Medical condition: The participants of this study have chronic obstructive pulmonary disease (COPD).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004462-40 Sponsor Protocol Number: TMC207-TiDP13-C208 Start Date*: 2007-12-20
    Sponsor Name:Tibotec BVBA
    Full Title: A Phase II, placebo-controlled, double-blind, randomized trial to evaluate the anti-bacterial activity, safety, and tolerability of TMC207 in subjects with sputum smear-positive pulmonary infection...
    Medical condition: Tuberculosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10044755 Tuberculosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LV (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 17:00:46 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA